Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2023: (Do not round intermediate calculations. Round final answers to nearest whole dollar.) *DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2023. Assume Kane Biotech has recorded no impairment losses in previous year Journal entry worksheet